A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Uncontrolled Severe Asthma

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE IIB, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO ASSESS THE EFFICACY AND SAFETY OF MSTT1041A IN PATIENTS WITH UNCONTROLLED SEVERE ASTHMA

Intervention/treatment:
MSTT1041A (RO7187807)
Medical condition:
ASTHMA
Protocol code:
GB39242
Control number:
197547
Status:
Closed
Approved:
September 09, 2016
Date Completed:
Trial phase:
Phase 2
For more information:
ClinicalTrials.gov - NCT02918019
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 75 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Medical Comunications
Organization
Hoffmann-La Roche
Phone:
1-800-821-8590
Sponsor
GENENTECH INC

Locations

Ontario

Aggarwal and Associates
Brampton, Ontario, L6T 0G1
Anil Dhar Professional Medicine Corporation
Windsor, Ontario, N8X 5A6
Cheema Research
Mississauga, Ontario, L5A 3V4
Inspiration Research
Toronto, Ontario, M5T 3A9

Quebec

C.I.C. Mauricie
Trois-Rivières, Quebec, G8T 7A1

Results

See the results from the trial NCT02918019. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?